Supplemental Materials_12.03.2024 Final 12.3.24 .xlsx

These supplementary materials related to the publication entitled: Optimizing Exclusion Criteria for Clinical Trials of Persistent Lyme Disease Using Real-World Data by Lorraine Johnson, JD, MBA, Mira Shapiro, MSc , Deanna Needell PhDand Raphael B. Stricker, MD. Abstract: Although eligibility criteria for clinical trials significantly impact study outcomes, these criteria are often established without scientific justification, leading to delayed recruitment, small sample sizes, and limited study generalizability. Persistent Lyme disease (PLD) presents unique challenges due to symptom variability, inconsistent treatment responses and the lack of reliable biomarkers, underscoring the need for scientifically justified eligibility criteria. <b>Objective:</b> This study examines the effects of commonly used enrollment criteria on sample yield in PLD clinical trials using real-world data (RWD) from the MyLymeData patient registry. The study also compares the effects of these criteria on enrollment for PLD versus acute Lyme disease (ALD) trials and evaluates the scientific rationale for each criterion. <b>Methods:</b> Data from 4,183 Lyme disease patients enrolled in the MyLymeData registry were analyzed to assess the prevalence and cumulative impact of various criteria on sample yield. A comparative analysis of cohorts with PLD (n=3,589) versus ALD (n=594) was conducted to identify differences in sample attrition. <b>Results:</b> In a large PLD cohort study, we found that current commonly used eligibility criteria would exclude approximately 90% of patients, significantly limiting study generalizability. Substantial differences in sample attrition between PLD and ALD cohorts highlight the need for tailored criteria. The strength of scientific justification varied widely among criteria. <b>Conclusion:</b> This study demonstrates the importance of using RWD to optimize eligibility criteria in PLD clinical trials. By providing insights into the balance between sample attrition and scientific justification, researchers can enhance trial feasibility, generalizability, and robustness. Our RWD sample demonstrates that researchers could substantially increase the sample yield from 10% to 64% by loosening restrictions on coinfections and misdiagnoses of chronic fatigue syndrome, fibromyalgia, and psychiatric conditions.